|
|
|
|
Tectonic Therapeutic Inc (NASDAQ: TECX) |
|
Price: $23.0000
$-0.50 
-2.128%
|
| Day's High:
| $23.47
| Week Perf:
| -0.76 %
|
| Day's Low: |
$ 22.50 |
30 Day Perf: |
13.92 % |
| Volume (M): |
34 |
52 Wk High: |
$ 61.07 |
| Volume (M$): |
$ 779 |
52 Wk Avg: |
$29.48 |
| Open: |
$23.01 |
52 Wk Low: |
$13.70 |
|
|
| Market Capitalization (Millions $) |
395 |
| Shares
Outstanding (Millions) |
17 |
| Employees |
77 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-67 |
| Cash Flow (TTM) (Millions $) |
285 |
| Capital Exp. (TTM) (Millions $) |
0 |
Tectonic Therapeutic Inc
Company Address: 490 Arsenal Way Watertown 2472 MA
Company Phone Number: 666-3320 Stock Exchange / Ticker: NASDAQ TECX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Sun, May 18 2025 11:00 AM UTC
Tectonic Therapeutic, Inc. (NASDAQ: TECX) recently shared the complete results from Part A of their Phase 1b clinical trial of TX45, a potential treatment for Group 2 Pulmonary Hypertension in patients with Heart Failure with preserved Ejection Fraction (HFpEF). These results, which represent a significant milestone for Tectonic s leading asset a long-acting relaxin therapy ...
|
| Product Service News
Published Mon, Nov 11 2024 10:00 AM UTC
Tectonic Therapeutics Makes Strides in Heart Failure Treatment with Promising TX45 Phase 1a Results On November 11, 2024, Tectonic Therapeutics, a clinical-stage biotechnology firm based in Watertown, Massachusetts, unveiled positive results from a Phase 1a trial for its lead therapeutic candidate, TX45. This innovative drug, formulated as a long-acting Fc-relaxin fusion pro...
|
| Clinical Study
Published Thu, Sep 19 2024 8:01 PM UTC
Tectonic Therapeutics, a clinical-stage biotechnology company, recently announced positive outcomes from the Phase 1a clinical trial of its lead investigational drug, TX45. The results underscore the drug s potential, showing a robust safety profile, absence of immunogenicity, and a favorable pharmacokinetic/pharmacodynamic (PK/PD) relationship. These findings have been inst...
|
| Per Share |
Current |
| Earnings (TTM) |
-13.59 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
16.61 $ |
| Cash |
17.85 $
|
| Book Value |
17.55 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-13.59 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
16.61 $ |
| Cash |
17.85 $
|
| Book Value |
17.55 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
